51 results about "Bronchiectasis" patented technology

The invention relates to a CT image data processing method and device, a storage medium and electronic equipment, and belongs to the technical field of data processing, and the method comprises the steps: generating a plurality of training sets according to the combination of the types of bronchiectasis lesions, different training sets comprising CT image data corresponding to different types of combinations of bronchiectasis lesions, the first annotation information comprises a bronchiectasis lesion included in the CT image and the type of the bronchiectasis lesion; according to the plurality of training sets in sequence, training to obtain a first processing model; acquiring CT image data of the lung; inputting the CT image data into a first processing model to obtain a bronchiectasia focus output by the first processing model and determined according to the CT image data, and the type of the bronchiectasia focus; and outputting a processing result of the CT image data according to the determined bronchiectasis focus and the type of the bronchiectasis focus.

The invention belongs to the technical field of animal model construction, and particularly relates to a construction method and application of a bronchiectasis animal model. According to the method, the bronchiectasis animal model is constructed in a manner of alternately infecting the animal with the self-separated pseudomonas aeruginosa and injecting the protease into the airway of the animal, so that the stable bronchiectasis animal model is successfully obtained, and the modeling success rate is relatively high. It is confirmed through imaging and pathological detection means that the constructed bronchiectasia animal model meets the diagnostic standard of bronchiectasia, chronic pseudomonas aeruginosa airway infection in bronchiectasia can be accurately simulated, structural changes of bronchiectasia are copied, and auxiliary clinical research and application are facilitated.

The present invention relates to the dipeptidyl-peptidase I (DPPI or Cathepsin C) inhibitor of formula (I), which is useful in the prevention and / or treatment of bronchiectasis with certain underlying aetiologies, in the prevention and / or treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis or hidradenitis suppurativa using therapeutically efficacious dosages and to polymorphs of Compound (I) as well as to pharmaceutical compositions comprising Compound (I) and its polymorphs.

This disclosure relates to anti-Pseudomonas Psl and PcrV bispecific antibodies for use in treatment of bronchiectasis.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

The invention belongs to the field of pharmaceutics, particularly relates to a composition containing levosalbutamol hydrochloride and ipratropium bromide as well as a preparation method and application of the composition, and overcomes the defects of a stabilizer disodium ethylene diamine tetraacetate adopted in the prior art. The invention provides a levosalbutamol hydrochloride and ipratropium bromide composition which is simpler in prescription and better in safety, can be used for treating reversible bronchospasm related to airway obstructive diseases, can jointly act on muscarinic acid and beta2 adrenergic receptors in the lung, can enhance the bronchiectasia effect, takes effect quickly, and is free of toxic and side effects. The clinical application value is very high.

Disclosed is a nitrile derivative compound represented by formula (I), a stereoisomer, a deuterated product, a co-crystal, a solvate or a pharmaceutically acceptable salt thereof, wherein each group is as defined in the description. The compound has dipeptidyl peptidase 1 inhibitory activity and can be used to prepare a drug for treating diseases including obstructive airway diseases, bronchiectasis, cystic fibrosis, asthma, emphysema, and chronic obstructive pulmonary diseases.

The invention belongs to the technical field of cell culture, and particularly relates to a bronchiectasis patient airway epithelial basal cell separation and culture method, which comprises: obtaining bronchial tissue of a bronchiectasis patient, stripping connective tissue of the bronchial tissue, and retaining cartilage rings; longitudinally cutting the completely stripped bronchial tissue along the tracheal ring to expose the inner membrane surface of the bronchial, then soaking the bronchial tissue in a Dispase II dispersing enzyme solution to digest, and collecting the dissociated bronchial tissue; the dissociated bronchial tissue is soaked in a Dispase II dispersozyme solution, and the bronchial tissue is blown and beaten; after blowing and beating are completed, stopping digestion by using a serum-free culture medium, and collecting a cell suspension; filtering and centrifuging the cell suspension, discarding supernate, and collecting precipitated cells; and placing the precipitated cells in an amplification culture medium for cell amplification and subculture. The purity of the airway epithelial basal cells of the bronchiectasis patient separated by the method is high, and the proliferation capacity and the reaction capacity of the cells are good.

The application discloses application of lactosylceramide in regulating inflammation related to bronchiectasis Pseudomonas aeruginosa infection. The application discloses, for the first time, the role of LacCer in amplification of inflammation related to bronchiectasis infection, proposes a new infection control mechanism from the perspective of metabolic regulation, and indicates that LacCer participates in regulation of inflammation by regulating the NLRP3 inflammasome related pathway, thereby providing a direction for targeted intervention. On this basis, the application further proves, through in-vivo experiments, that inhibition of LacCer synthesis can intervene in inflammation and lung injury related to bronchiectasis infection, thereby providing a new potential treatment strategy for control of inflammation related to bronchiectasis infection.

The invention relates to medical uses of alvelestat, and pharmaceutically acceptable salts thereof, in the treatment of non-cystic fibrosis bronchiectasis.

Disclosed herein are methods of decreasing mucus hypersecretion in the lungs comprising administering an effective amount of a MUC1 inhibitor to a subject in need thereof. In certain embodiments, the MUC1 inhibitor is the peptide GO-201, GO-203, or GO-203-2C. In certain embodiments, the subject is a human patient. In certain embodiments, the subject is diagnosed with rhinosinusitis, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiectasis, asthma, idiopathic pulmonary fibrosis, acute respiratory distress syndrome (ARDS), cystic fibrosis, or a respiratory syncytial virus (RSV) infection.

The invention relates to a pharmaceutical composition containing a dipeptidyl peptidase 1 (DPP1) small-molecule inhibitor compound A, a preparation method of the pharmaceutical composition, and application of the pharmaceutical composition in treatment of diseases or conditions related to fibrosis bronchiectasis, in particular to a pharmaceutical composition containing a dipeptidyl peptidase 1 (DPP1) small-molecule inhibitor compound A, a preparation method of the pharmaceutical composition and application of the pharmaceutical composition in treatment of fibrosis bronchiectasis related diseases or conditions.

A compact, hands-free, oral positive expiratory pressure (PEP) device designed to optimize respiratory mechanics by providing controlled resistance during exhalation. The device slows the respiratory rate, prolongs exhalation, generates positive airway pressure, and thereby reduces breathlessness, enhances oxygenation, and expands functional lung capacity. It is particularly beneficial in conditions such as chronic obstructive pulmonary disease (COPD), tracheobronchomalacia, excessive dynamic airway collapse (EDAC), bronchiectasis, atelectasis, and acute respiratory distress syndromes, while also serving broader functions like stress reduction, cardiovascular support, and respiratory muscle training. The device is lightweight, portable, and lanyard-supported, allowing continuous availability for daily use and physical activity. Structurally, it is conical, features a primary airflow chamber, a mouth opening, and one or more resistance orifices that regulate exhalation pressure. By maintaining consistent PEP levels (ranging approximately 4-15 cm H2O), the device helps prevent airway collapse, promotes alveolar recruitment, and improves the ventilation-perfusion ratio.

Disclosed are compositions and methods for treating, amelioriating, reversing and / or preventing (acting as a prophylaxis): a respiratory condition involving an infection or an inflammation, or any lung condition involving inflammation or infection, e.g., of a respiratory mucosa, and / or an infection or an inflammation of an underlying muscle of the respiratory tract; or, an asthma; a bronchitis; a sinusitis or rhinosinusitis; an infection of a sinus; chronic obstructive airway disease; emphysema; chronic bronchitis; pneumonia; or, a bronchiectasis. In alternative embodiments, the therapeutic combination comprises an orally administered Amphotericin B or equivalent antifungal alone, or a combination of Amphotericin B and: one antibiotic; two antibiotics; three antibiotics; or, four or more antibiotics. In alternative embodiments, these compositions and methods are dosaged and administered to children in need thereof. In alternative embodiments, compositions and methods of the invention are dosaged, formulated and dosaged as tablet, capsule, liquid, powder or aerosol preparations or formulations, or preparations or formulations for oral delivery or inhalation.

Disclosed in the present invention are a polymorph of a benzo[c]chroman compound, a preparation method therefor and use thereof. The present invention particularly provides a polymorph of a compound represented by formula I, a preparation method therefor and use thereof. The compound represented by formula I is used as a cathepsin C inhibitor, and a crystalline form of the compound and a pharmaceutical composition comprising the crystalline form can be used for treating asthma, obstructive pulmonary diseases, bronchiectasis, ANCA-related vasculitis, psoriasis, α1-antitrypsin deficiency, lupus nephritis, diabetes, inflammatory bowel diseases, rheumatic arthritis, rhinosinusitis, hidradenitis suppurativa or cancers.

This disclosure provides pharmaceutical preparations, products, and methods relating to ARINA-1 for use in treating patients with chronic inflammatory lung diseases, such as lung transplant, cystic fibrosis (CF), non-CF bronchiectasis, chronic obstructive pulmonary disease (COPD), and other inflammatory lung diseases.

The present invention relates to the dipeptidyl-peptidase I (DPPI or Cathepsin C) inhibitor of formula (I), which is useful in the prevention and / or treatment of bronchiectasis with certain underlying aetiologies, in the prevention and / or treatment of anti-neutrophil cytoplasmic anti- body-associated vasculitis or hidradenitis suppurativa using therapeutically efficacious dosages and to polymorphs of Compound (I) as well as to pharmaceutical compositions comprising Compound (I) and its polymorphs.

Aspects of the present disclosure provide compositions comprising NEK10 for example, wild-type NEK10 or a hyperactive NEK10 mutant such as NEK10S684D, and methods of using such for treating a respiratory disorder such as bronchiectasis.

Provided herein are methods of treating bronchiectasis with an antibody which binds IL-33 and inhibits its activation of EGFR / RAGE. The antibody may be tozorakimab.

The present invention relates to a method for the prognosis of acute exacerbation in bronchiectasis using an artificial intelligence model. The method processes clinical data such as BSI and / or FACED scores and demographic information as input, handles missing values, and standardizes the data. The standardized data undergo four-fold cross-validation and are analyzed using a multilayer perceptron (MLP) model to acquire outputs through which the acute exacerbation of bronchiectasis can be prognosed. Through the process of analyzing and training with the input data, weights are assigned to individual clinical indicators, thereby improving the accuracy of the output, that is, the prediction results.

The present invention relates to methods of using compounds of Formula I,wherein R1a, R1b, R2, R3, R4, W, Y, and Z are as described herein, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compound, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjögren's Syndrome, and other CFTR associated disorders.

Disclosed are polymorphs of benzo[c]chromane compounds, and preparation methods and uses thereof, and specifically provided are polymorphs of a compound shown in formula I, and preparation methods and uses thereof. The compound shown in formula I is a cathepsin C inhibitor, and the crystal form and the pharmaceutical composition containing the crystal form can be used for treating asthma, obstructive pulmonary disease, bronchiectasis, ANCA-associated vasculitis, psoriasis, alpha 1-antitrypsin deficiency, lupus nephritis, diabetes, inflammatory bowel disease, rheumatoid arthritis, sinusitis, hidradenitis suppurativa or cancer.

The application belongs to the technical field of medicine, and particularly relates to a traditional Chinese medicine composition for treating bronchiectasis. The traditional Chinese medicine composition is composed of the following traditional Chinese medicines: rhizoma phragmitis, raw semyen of job's tears, winter melon seed, persicae semen, platycodon grandiflorum, semen balsamni, dioscorea, prepared rhizome of rehmannia, radix codonopsis, pinellia ternata, poria cocos and pericarpium citri reticulatae. The traditional Chinese medicine composition is combined together, and through scientific compounding, each medicine plays a synergistic effect, realizes a significant treatment effect on bronchiectasis, has a high clinical application value, and has a wide application prospect.

The present invention discloses a nitrile derivative compound represented by formula (I), its stereoisomers, deuterated compounds, co-crystals, solvates or pharmaceutically acceptable salts, and each group is as defined in the specification. The compound has dipeptidyl peptidase 1 inhibitory activity and can be used for preparing drugs for treating diseases including airway obstructive diseases, bronchiectasis, cystic fibrosis, asthma, emphysema and chronic obstructive pulmonary disease, etc.

The invention discloses a traditional Chinese medicine composition for treating bronchiectasis diseases. The traditional Chinese medicine composition is prepared from, by weight, 10-40 parts of cortex mori, 10-30 parts of wild buckwheat, 5-15 parts of radix scutellariae, 10-20 parts of fructus trichosanthis, 5-15 parts of semen armeniacae amarae, 5-15 parts of rhizoma pinellinae praeparata, 5-15 parts of cortex moutan, 10-20 parts of herba agrimoniae and 10-20 parts of radix adenophorae. The traditional Chinese medicine composition disclosed by the invention has the main effects of clearing lung and reducing phlegm, regulating qi and relieving cough, and reinforcing qi and nourishing yin to treat bronchiectasis caused by phlegm-heat obstructing lung and qi-yin impairment syndromes, especially bronchiectasis acute exacerbation, and has a good clinical application effect; the symptoms such as cough, expectoration and hemoptysis of patients in the acute exacerbation period of bronchiectasis are effectively improved, the life quality of the patients is remarkably improved, and the traditional Chinese medicine composition has great curative effect advantages and treatment potential.

The present invention provides a stable pharmaceutical composition to be used with pressurized metered dose inhalers comprising a beta 2 agonist, a corticosteroid, a muscarinic antagonist, HFO propellant, a co-solvent, an organic acid(s) and optionally water. The invention further provides a specific container and a valve system comprising internally coated canister and a valve for storing the composition. The invention also provides a pharmaceutical composition comprising a beta 2 agonist, a corticosteroid, a muscarinic antagonist for the treatment or prophylaxis of asthma, chronic obstructive pulmonary disease (COPD), rhinitis or as adjunct therapy for cystic fibrosis, non-cystic fibrosis bronchiectasis, lung infections or pulmonary fibrosis.

The invention discloses an internal traditional Chinese medicine composition and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine, and the traditional Chinese medicine for pulmonary fibrosis comprises 28-31 g of bletilla striata, 9-11 g of donkey-hide gelatin, 9-11 g of astragalus membranaceus and 4-6 g of pseudo-ginseng. Therefore, the invention provides the traditional Chinese medicine composition for internal use as well as the preparation method and the application thereof, and the traditional Chinese medicine composition for internal use is used for treating chronic gastritis, gastroduodenal ulcer complicated with perforation bleeding; chronic tracheitis, bronchiectasis and bleeding; the traditional Chinese medicine composition has good prevention and treatment effects on both pulmonary fibrosis and lithiasis.

The invention relates to specific polyglycerol derivatives and their further medical uses, namely to dPG / lPG-DTBA and dPG / lPG-cysteamine. These polyglycerol derivatives have a linear or dendritic polyglycerol backbone and carry at least one thiol group covalently bound to the polyglycerol backbone. The claimed medical uses are the use as mucolytic; the use in treating chronic sinusitis, asthma, chronic bronchitis, cystic fibrosis, chronic obstructive pulmonary disease, emphysema, or bronchiectasis; and the use in treating chronic inflammatory bowel diseases, constipation, gastrointestinal malabsorption syndrome, irritable bowel syndrome, steatorrhea or diarrhea.

The present invention relates to the dipeptidyl-peptidase I (DPPI or Cathepsin C) inhibitor of formula (I), which is useful in the prevention and / or treatment of bronchiectasis with certain underlying aetiologies, in the prevention and / or treatment of anti-neutrophil cytoplasmic anti- body-associated vasculitis or hidradenitis suppurativa using therapeutically efficacious dosages and to polymorphs of Compound (I) as well as to pharmaceutical compositions comprising Compound (I) and its polymorphs.

A pharmaceutically acceptable salt of a benzo[c]chroman compound and a polymorphic form and use of the pharmaceutically acceptable salt. The pharmaceutically acceptable salt is selected from hydrochloride, methanesulfonate, phosphate, L-tartrate, maleate, p-toluenesulfonate, sulfate, fumarate, succinate, citrate, malate, and hydrobromide. The pharmaceutically acceptable salt and the polymorphic form thereof improve the bioavailability and the stability, and as a cathepsin C inhibitor, can be used for treating asthma, obstructive pulmonary disease, bronchiectasis, ANCA-associated vasculitis, psoriasis, α1-antitrypsin deficiency, lupus nephritis, diabetes, inflammatory bowel disease, rheumatoid arthritis, sinusitis, hidradenitis suppurativa, or cancer.